Blocking YAP1/TEAD complexes restored trastuzumab sensitivity, suggesting that dual targeting of HER2 and YAP1/TEAD could improve outcomes in HER2-positive breast cancer individuals (González-Alonso et al., 2020[38]). Here, YAP1 is linked to breast carcinoma.